concept

MEMANTINE

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about MEMANTINE: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

134Connections

0Hypotheses

0Analyses

48Outgoing

49Incoming

No summary available yet. View on Wiki →

💡 Concept Info

Name	MEMANTINE
Summary	Page for Memantine - NMDA Antagonist for Alzheimer's Disease
Key Genes/Proteins	TAU, AKT, NMDAR
Related Diseases	INFLAMMATION, NEURODEGENERATION
Related Pathways	CREB/RCAN1, Nrf2

Wiki Pages (21)

Knowledge base pages for this entity

Canonical Page

Pathway Diagram

graph TD
    MEMANTINE["MEMANTINE"]
    MEMANTINE -->|"inhibits"| NMDA_RECEPTOR["NMDA RECEPTOR"]
    MEMANTINE -->|"treats"| Dementia["Dementia"]
    MEMANTINE -->|"treats"| Alzheimer_S_Disease["Alzheimer'S Disease"]
    MEMANTINE -->|"treats"| Moderate_To_Severe_Dementia["Moderate To Severe Dementia"]
    MEMANTINE -->|"treats"| Alzheimer_s_Disease["Alzheimer's Disease"]
    MEMANTINE -->|"promotes"| Functional_Stabilization["Functional Stabilization"]
    MEMANTINE -->|"activates"| NRF2["NRF2"]
    MEMANTINE -->|"activates"| NMDA["NMDA"]
    ALZHEIMER_S_DISEASE["ALZHEIMER'S DISEASE"] -->|"target for"| MEMANTINE
    DEMENTIA["DEMENTIA"] -->|"inhibits"| MEMANTINE
    CREB["CREB"] -->|"activates"| MEMANTINE
    EXCITOTOXICITY["EXCITOTOXICITY"] -->|"activates"| MEMANTINE
    DONEPEZIL["DONEPEZIL"] -->|"activates"| MEMANTINE
    APP["APP"] -->|"produces"| MEMANTINE

Outgoing (84)

Target	Relation	Type	Str
CREB/RCAN1	activates	pathway	0.80
Nrf2	activates	pathway	0.80
NEURON	protects_against	cell_type	0.65
NEURONS	protects_against	cell_type	0.65
TAU	transports	gene	0.65
TAU	phosphorylates	gene	0.65
AKT	inhibits	gene	0.65
AKT	regulates	gene	0.65
AKT	treats	gene	0.65
NMDAR	inhibits	gene	0.65
NMDAR	regulates	gene	0.65
NMDAR	treats	gene	0.65
INFLAMMATION	activates	phenotype	0.65
NEURODEGENERATION	inhibits	phenotype	0.65
NEURODEGENERATION	regulates	phenotype	0.65
NEURODEGENERATION	exacerbates	disease	0.65
NEURODEGENERATION	activates	disease	0.65
MICROGLIA	treats	cell_type	0.65
ALZHEIMERS_DISEASE	treats	disease	0.64
AMYLOID	associated_with	protein	0.50
PARKINSON	associated_with	disease	0.50
DEMENTIA	associated_with	disease	0.45
MELATONIN	associated_with	drug	0.45
NRF2	associated_with	gene	0.45
CREB	associated_with	gene	0.45
ALZHEIMER	associated_with	disease	0.45
GLUTAMATE	associated_with	phenotype	0.45
NEURONS	associated_with	cell_type	0.45
TAU	associated_with	protein	0.45
AKT	associated_with	gene	0.45
PRAMIPEXOLE	associated_with	drug	0.45
RIVASTIGMINE	associated_with	drug	0.45
TAU PHOSPHORYLATION	associated_with	phenotype	0.45
RIBOSOME	associated_with	organelle	0.45
NMDAR	associated_with	gene	0.45
RILUZOLE	associated_with	drug	0.45
MICROGLIA	associated_with	cell_type	0.45
NEURON	associated_with	cell_type	0.45
MTOR	associated_with	gene	0.45
AMPK	associated_with	gene	0.45
BDNF	associated_with	gene	0.45
PRAMIPEXOLE	activates	drug	0.35
NEURON	activates	cell_type	0.35
TAU	produces	protein	0.35
TAU	inhibits	protein	0.35
TAU	therapeutic_target	protein	0.35
TAU	activates	protein	0.35
ad_clinical_trial_failures:memantine	data_in	dataset_row	0.00

Incoming (50)

Source	Relation	Type	Str
ALZHEIMER	treats	disease	0.65
ALZHEIMER'S DISEASE	treats	disease	0.65
CHOLINERGIC	promotes	cell_type	0.65
DONEPEZIL	promotes	drug	0.65
APP	transports	gene	0.65
ALZHEIMER	causes	disease	0.65
ALZHEIMER'S DISEASE	regulates	disease	0.65
AKT	phosphorylates	gene	0.65
GALANTAMINE	activates	drug	0.65
RIBOSOME	produces	organelle	0.65
NEURON	treats	cell_type	0.65
EMPAGLIFLOZIN	treats	drug	0.65
INFLAMMATION	associated_with	phenotype	0.50
CHOLESTEROL	associated_with	phenotype	0.50
ACETYLCHOLINE	associated_with	phenotype	0.50
NEURODEGENERATION	associated_with	phenotype	0.50
DOPAMINERGIC NEURONS	associated_with	cell_type	0.50
PARKINSON'S DISEASE	associated_with	disease	0.50
NRF2 PATHWAY	associated_with	pathway	0.45
PRAMIPEXOLE	associated_with	drug	0.45
ALZHEIMER'S DISEASE	associated_with	disease	0.45
EXCITOTOXICITY	associated_with	phenotype	0.45
RIVASTIGMINE	associated_with	drug	0.45
GALANTAMINE	associated_with	drug	0.45
DONEPEZIL	associated_with	drug	0.45
TAU PHOSPHORYLATION	associated_with	phenotype	0.45
DEMENTIA	associated_with	disease	0.45
CREB	associated_with	gene	0.45
MELATONIN	associated_with	drug	0.45
ALZHEIMER	associated_with	disease	0.45
GLUTAMATE	associated_with	phenotype	0.45
AKT	associated_with	gene	0.45
GLUTAMATE EXCITOTOXICITY	associated_with	phenotype	0.45
NEUROINFLAMMATION	associated_with	phenotype	0.45
COGNITIVE DECLINE	associated_with	phenotype	0.45
EMPAGLIFLOZIN	associated_with	drug	0.45
BARICITINIB	associated_with	drug	0.45
TIDEGLUSIB	associated_with	drug	0.45
ALZHEIMER'S DISEASE	therapeutic_target	disease	0.35
DEMENTIA	inhibits	disease	0.35
CREB	activates	gene	0.35
EXCITOTOXICITY	activates	process	0.35
DONEPEZIL	activates	drug	0.35
APP	produces	gene	0.35
APP	inhibits	gene	0.35
APP	therapeutic_target	gene	0.35
ALZHEIMER'S DISEASE	activates	disease	0.35
AKT	activates	gene	0.35
ad_clinical_trial_failures:memantine	data_in	dataset_row	0.00

Targeting Hypotheses (0)

Hypotheses where this entity is a therapeutic target

Hypothesis	Score	Disease	Analysis
No targeting hypotheses

Mentioning Analyses (0)

Scientific analyses that reference this entity

No analyses mention this entity

Related Papers (0)

Scientific publications cited in analyses involving this entity

Title & PMID	Authors	Journal	Year	Citations
No papers found

MEMANTINE

Understanding Entity Pages

Wiki Pages (21)

Memantine - NMDA Antagonist for Alzheimer's Disease

Clinical Management Guide for CBS/PSP

Progressive Supranuclear Palsy (PSP)

Corticobasal Syndrome (CBS)

Novel Therapy Index

primary-progressive-aphasia

calcium-dysregulation-comparison

Section 148: Advanced Nutritional Biochemistry in CBS/PSP

Therapeutics

Frontotemporal Dementia (FTD) Mechanistic Pathway

Alzheimer's Disease

Frontotemporal Dementia (FTD)

ALS Failed Approaches Analysis

APOC4 — Apolipoprotein C-IV

Huntington's Disease

Vascular Cognitive Impairment (VCI)

Rapamycin ALS Trial - mTOR Inhibition for Amyotrophic Lateral Sclerosis

dimethyl-fumarate-nrf2-ad-nct06850597

A Phase 3, Randomised, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy, Tolerability, and Safety of Combined Metabolic Activator Supplementation in Subjects Diagnosed With Alzheimer's Disease